Sangamo BioSciences (SGMO) Stock Soars on First-In-Man Study of Genome Editing Tech

Shares of Sangamo Biosciences Inc. (SGMO) were trading at $23.50, up +3.89 or +19.84 percent in pre-market trading Thursday morning, after news late yesterday that the New England Journal of Medicine was publishing results of the first study of the company’s proprietary zinc finger nuclease (ZFN) genome editing technology in human beings. Sangamo Bio stock Read the full article... Read the rest of Sangamo BioSciences (SGMO) Stock Soars on First-In-Man Study of Genome Editing Tech at InvestorGuide.com .